All In Biotech

Drug Trial Radar · NCT07609108

Pridopidine Phase 3 Study in Huntington's Disease

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants With Huntington's Disease (HD)

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Jul 1, 2026

Primary completion

Jun 2028

Study completion Jun 2030

Sponsor

Lead sponsor
PrileniaIndustry
Sponsor type
Industry
Collaborators
Ferrer Internacional S.A.
First posted
May 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 23 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if pridopidine can slow the clinical decline of Huntington's Disease (HD) in adult participants. It will also inform about the safety of pridopidine. The main questions the study aims to answer are: Does pridopidine slow the overall worsening of HD over 1 year? Does pridopidine slow the worsening of specific aspects of HD over 1 year, namely the clinical progression, the ability to perform daily life activities (functional capacity), the mind's ability to process information (cognition), working of the muscles (motor function), and quality of life? Researchers will compare the drug pridopidine to a placebo (a look-alike substance that contains no drug) to see if pridopidine works better than placebo to treat HD. During the first year of the study, participants will have the same chance to receive either pridopidine or placebo. Participants will: Take 1 pridopidine or placebo capsule twice daily for 12 months. Visit the clinic 6 times within 1 year for checkups and tests. All participants who complete this 1-year placebo-controlled study period will roll over into an additional 2-year study period during which all participants will receive pridopidine treatment, including participants who had received placebo during the first year. During this additional 2-year treatment period participants will visit the clinic a total of 6 times for checkups and tests.

Conditions

  • Huntington Disease

Interventions

  • PridopidineDrug

    Pridopidine hard gelatin capsule

  • PlaceboDrug

    Matched placebo hard gelatin capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Composite Unified Huntington's Disease Rating Scale (cUHDRS)Time frame: Change from Baseline to Week 52

Locations

66 sites in 12 countries. Site status is shown where the registry gives one.

  • The University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • University of California, San Diego

    La Jolla, California · Recruiting

  • UCLA Medical Center

    Los Angeles, California · Not yet recruiting

  • UC Davis Medical Center

    Sacramento, California · Not yet recruiting

  • Georgetown University

    Washington D.C., District of Columbia · Not yet recruiting

  • University of Miami-U Health Boca Raton

    Boca Raton, Florida · Not yet recruiting

  • University of Florida (Norman Fixel Institute for Neurological Diseases)

    Gainesville, Florida · Not yet recruiting

  • Northwestern University

    Chicago, Illinois · Not yet recruiting

  • Rush University Medical Center

    Chicago, Illinois · Not yet recruiting

  • University of Kansas Medical Center

    Kansas City, Kansas · Not yet recruiting

  • Hereditary Neurological Disease Centre

    Wichita, Kansas · Recruiting

  • Johns Hopkins University

    Baltimore, Maryland · Not yet recruiting

  • Massachusetts General Hospital

    Charlestown, Massachusetts · Not yet recruiting

  • Struthers Parkinson's Center / Health Partners Institute

    Golden Valley, Minnesota · Recruiting

  • Columbia University

    New York, New York · Recruiting

  • Duke University

    Durham, North Carolina · Recruiting

  • University of Cincinnati

    Cincinnati, Ohio · Not yet recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • The Ohio State University

    Columbus, Ohio · Recruiting

  • Oregon Health and Science University (OHSU)

    Portland, Oregon · Not yet recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

  • UT Health, Houston, McGovern Medical School

    Houston, Texas · Recruiting

  • University of Vermont Medical Center

    Burlington, Vermont · Not yet recruiting

  • EvergreenHealth Research Department

    Kirkland, Washington · Not yet recruiting

  • University of Washington

    Seattle, Washington · Recruiting

  • Hopital Erasme

    Anderlecht, Belgium · Not yet recruiting

  • Cliniques Universitaires Saint-Luc

    Woluwe-Saint-Lambert, Belgium · Not yet recruiting

  • University of Calgary

    Calgary, Alberta, Canada · Not yet recruiting

  • University of Alberta

    Edmonton, Alberta, Canada · Not yet recruiting

  • University of British Columbia

    Vancouver, British Columbia, Canada · Not yet recruiting

  • North York General Hospital

    Toronto, Ontario, Canada · Not yet recruiting

  • Centre Hospitalier de l'Universite de Montreal (CHUM)

    Montreal, Quebec, Canada · Not yet recruiting

  • Vseobecna Fakultni Nemocnice V Praze

    Prague, Czechia · Not yet recruiting

  • Centre Hospitalier Universitaire D'Angers

    Angers, France · Not yet recruiting

  • CHU Henri Mondor (APHP)

    Créteil, France · Not yet recruiting

  • Centre Hospitalier Universitaire Grenoble Alpes

    La Tronche, France · Not yet recruiting

  • Centre Hospitalier Regional De Marseille

    Marseille, France · Withdrawn

  • Universitaetsklinikum Aachen AöR

    Aachen, Germany · Not yet recruiting

  • Katholisches Klinikum Bochum gGmbH

    Bochum, Germany · Not yet recruiting

  • Universitätsklinikum Erlangen

    Erlangen, Germany · Not yet recruiting

Showing 40 of 66 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.